Ozempic and GLP-1 Cost Guide: Insurance, Compounding, and Savings

GLP-1 receptor agonists (glucagon-like peptide-1) work by mimicking a hormone that regulates blood sugar and appetite. They have become the most commercially successful drug class in history, generating over $50 billion in annual global revenue. But their list prices remain staggering compared to what they cost to produce.

It is worth noting that Eli Lilly has introduced Zepbound single-dose vials at $299/month (2.5 mg or 5 mg) and $549/month (10 mg, 12.5 mg, or 15 mg) through its LillyDirect platform. Novo Nordisk has launched a self-pay price for oral Wegovy at $149/month. These represent real progress, but they still leave many patients paying far more than the drugs cost to manufacture.

Whether insurance covers your GLP-1 medication depends almost entirely on two factors: your diagnosis and your plan type. The coverage landscape is fragmented and often frustrating.

The Diabetes vs. Weight Loss Coverage Gap

This gap creates a two-tier system. A patient with type 2 diabetes can often get Ozempic or Mounjaro covered with a manageable copay. A patient with a BMI of 35 and sleep apnea who needs Wegovy or Zepbound for weight management may face the full list price. The same molecule (semaglutide) is covered or denied based on the diagnosis code, not the patient's clinical need.

Some doctors work around this by prescribing Ozempic off-label for patients with obesity who also have insulin resistance, pre-diabetes, or metabolic syndrome. This is a legitimate clinical decision, but it depends on the individual prescriber and the plan's formulary rules.

Nearly every insurer requires prior authorization for GLP-1 drugs. Getting approved takes preparation. Here is what works.

If your prior authorization is denied, you have the right to appeal. Most patients never appeal, which insurers count on. The success rate for well-documented appeals is surprisingly high.

Both Novo Nordisk and Eli Lilly offer savings programs that can dramatically reduce your cost, but the eligibility rules matter.

For more on patient assistance programs (including income thresholds and application tips), see our complete guide to patient assistance programs.

Compounded GLP-1 medications have become a major market in their own right, driven by the enormous price gap between brand drugs and compounded alternatives. But this space is complicated, legally evolving, and carries real risks worth understanding.

What Are Compounding Pharmacies?

Compounding pharmacies prepare customized medications based on a prescriber's order. There are two types that matter here:

Cost Comparison

Risks and Considerations

The Regulatory Landscape (2026)

The FDA removed semaglutide from its drug shortage list in February 2025, which eliminated the shortage-based justification for 503B outsourcing facilities to compound it. In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely. If finalized, this would effectively end large-scale compounding of these drugs.

However, 503A pharmacies (state-licensed, patient-specific) can still compound semaglutide and tirzepatide with a valid prescription. The legal battles between brand manufacturers and compounders are ongoing in multiple federal courts. Patients currently using compounded GLP-1s should stay informed about regulatory changes that could affect availability.

If you are considering a compounded GLP-1, verify that the pharmacy is properly licensed in your state, ask about their quality testing procedures, and discuss the option with your prescriber. This is not a decision to make based on price alone.

Canadian Pharmacies

Many Americans purchase Ozempic from licensed Canadian pharmacies at approximately $250 to $310 per month, a significant discount from the U.S. list price. Brand Ozempic is widely available through Canadian online pharmacies that ship to the U.S.

UK and Other International Options

Ozempic is available in the UK through online pharmacies at roughly $200 to $350 per month. However, shipping cold-chain injectable medications internationally adds complexity and risk. Ensure the pharmacy maintains proper temperature control during transit and has a verifiable regulatory license.

Telehealth Prescribers

Dozens of telehealth platforms now specialize in GLP-1 prescriptions, including Ro, Hims/Hers, Found, Calibrate, and others. These services typically charge a monthly consultation fee ($30 to $99) on top of the medication cost. Some partner with compounding pharmacies to offer bundled pricing.

When evaluating telehealth GLP-1 providers, ask: Does the prescriber conduct a real medical evaluation? Are they prescribing FDA-approved medications or compounded versions? What happens if you have side effects? How do they handle dosage titration? A legitimate telehealth provider should function like a real medical practice, not just a prescription mill.

If you rely on a manufacturer savings card for your GLP-1, you need to understand copay accumulators. This is one of the most consequential (and least understood) tricks in pharmacy benefit design.

Here is how it works: traditionally, when a manufacturer savings card covers your copay, that payment counts toward your annual deductible and out-of-pocket maximum. Once you hit your max, insurance picks up the full cost.

With a copay accumulator program, your insurer accepts the manufacturer's payment but does not count it toward your deductible or out-of-pocket maximum. This means you can use up your entire savings card benefit (often $3,000 to $5,000 per year) without making any progress on your deductible. Once the card runs out, you face full cost-sharing, and the sticker shock hits hard.

Check your plan documents or call your PBM to ask whether your plan uses a copay accumulator or copay maximizer program. Some states have passed laws banning accumulator programs, but enforcement varies. This is especially important for expensive specialty drugs like GLP-1s.

Related Guides